Advertisement

Citations to this article

Abstract

Personalized cancer medicine is based on the concept that targeted therapies are effective on subsets of patients whose tumors carry specific molecular alterations. Several mammalian target of rapamycin (mTOR) inhibitors are in preclinical or clinical trials for cancers, but the molecular basis of sensitivity or resistance to these inhibitors among patients is largely unknown. Here we have identified oncogenic variants of phosphoinositide-3-kinase, catalytic, α polypeptide (PIK3CA) and KRAS as determinants of response to the mTOR inhibitor everolimus. Human cancer cells carrying alterations in the PI3K pathway were responsive to everolimus, both in vitro and in vivo, except when KRAS mutations occurred concomitantly or were exogenously introduced. In human cancer cells with mutations in both PIK3CA and KRAS, genetic ablation of mutant KRAS reinstated response to the drug. Consistent with these data, PIK3CA mutant cells, but not KRAS mutant cells, displayed everolimus-sensitive translation. Importantly, in a cohort of metastatic cancer patients, the presence of oncogenic KRAS mutations was associated with lack of benefit after everolimus therapy. Thus, our results demonstrate that alterations in the KRAS and PIK3CA genes may represent biomarkers to optimize treatment of patients with mTOR inhibitors.

Authors

Federica Di Nicolantonio ... Stefano Biffo, Alberto Bardelli

×

Total citations by year in Crossref

Year: 2014 2013 2012 2011 2010 Total
Citations: 19 25 21 19 1 85
Citation information

Citations to this article in Crossref (85)

Title and authors Publication Year
PI3K/AKT signaling pathway and cancer: an updated review
M Martini, MC de Santis, L Braccini, F Gulluni, E Hirsch
Annals of Medicine 2014
MicroRNA and signaling pathways in gastric cancer
Z Zhang, Z Li, Y Li, A Zang
Cancer Gene Therapy 2014
Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma
S Bisht, F Ahmad, S Sawaimoon, S Bhatia, BR Das
Medical Oncology 2014
Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
F Janku, DS Hong, S Fu, SA Piha-Paul, A Naing, GS Falchook, AM Tsimberidou, VM Stepanek, SL Moulder, JJ Lee, R Luthra, RG Zinner, RR Broaddus, JJ Wheler, R Kurzrock
Cell Reports 2014
Analysis of Molecular Cytogenetic Changes in Metastatic Renal Cell Carcinoma in the Setting of Everolimus Treatment: A Pilot Project
IR Caldwell, P Oei, D Ng, B Caudwell, PC Fong, RJ Broom
Clinical Genitourinary Cancer 2014
Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
MS Matter, T Decaens, JB Andersen, SS Thorgeirsson
Journal of Hepatology 2014
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study
SM Campos, WE Brady, KM Moxley, RE O'Cearbhaill, PS Lee, PA DiSilvestro, J Rotmensch, PG Rose, PH Thaker, DM O'Malley, P Hanjani, RE Zuna, ML Hensley
Gynecologic Oncology 2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
M Wang, LL Popplewell, RH Collins, JN Winter, A Goy, MS Kaminski, NL Bartlett, PB Johnston, J Lister, SR Fanning, JM Tuscano, JT Beck, H Kaya, A Robeva, J Fan, J Klimovsky, W Cheung, A Cherfi, OA O'Connor
British Journal of Haematology 2014
Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents
HK Kim, JE Green
Pharmacogenomics 2014
Precision medicine for metastatic renal cell carcinoma
G Sonpavde, TK Choueiri
Urologic Oncology: Seminars and Original Investigations 2014
mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review
N Husseinzadeh, HD Husseinzadeh
Gynecologic Oncology 2014
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
SM Leto, L Trusolino
Journal of Molecular Medicine 2014
Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?
ÁH Garces, MS Dias, E Paulino, CG Ferreira, AC de Melo
Cancer Chemotherapy and Pharmacology 2014
The Search Continues: Looking for Predictive Biomarkers for Response to Mammalian Target of Rapamycin Inhibition in Endometrial Cancer
LA Meyer, BM Slomovitz, B Djordjevic, SN Westin, DA Iglesias, MF Munsell, Y Jiang, R Schmandt, RR Broaddus, RL Coleman, JM Galbincea, KH Lu
International Journal of Gynecological Cancer 2014
PIK3CA Mutations in Mucinous Cystic Neoplasms of the Pancreas:
D Garcia-Carracedo, ZM Chen, W Qiu, AS Huang, SM Tang, RH Hruban, GH Su
Pancreas 2014
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
J Polivka, F Janku
Pharmacology & Therapeutics 2014
Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment
H Cheng, M Shcherba, G Pendurti, Y Liang, B Piperdi, R Perez-Soler
Lung Cancer Management 2014
Dual Inhibition of Phosphatidylinositol 3′-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach for Mucinous Adenocarcinoma of the Ovary:
A Kudoh, T Oishi, H Itamochi, S Sato, J Naniwa, S Sato, M Shimada, J Kigawa, T Harada
International Journal of Gynecological Cancer 2014
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
J Rodon, I Braña, LL Siu, MJ Jonge, N Homji, D Mills, E Tomaso, C Sarr, L Trandafir, C Massacesi, F Eskens, JC Bendell
Investigational New Drugs 2014
Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation: Acquired resistance to sunitinib in RCC
I Sakai, H Miyake, M Fujisawa
BJU International 2013
Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?
A Britschgi, T Radimerski, M Bentires-Alj
Drug Resistance Updates 2013
Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux
F Lin, MC de Gooijer, D Hanekamp, D Brandsma, JH Beijnen, O Tellingen
CNS Oncology 2013
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
CX Ma, VJ Suman, M Goetz, P Haluska, T Moynihan, R Nanda, O Olopade, T Pluard, Z Guo, HX Chen, C Erlichman, MJ Ellis, GF Fleming
Breast Cancer Research and Treatment 2013
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
V Serra, PJ Eichhorn, C García-García, YH Ibrahim, L Prudkin, G Sánchez, O Rodríguez, P Antón, JL Parra, S Marlow, M Scaltriti, J Pérez-Garcia, A Prat, J Arribas, WC Hahn, SY Kim, J Baselga
Journal of Clinical Investigation 2013
ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas
EP Samartzis, A Noske, KJ Dedes, D Fink, P Imesch
International journal of molecular sciences 2013

Advertisement
Advertisement